越涨越买！两日吸金超14亿

Group 1: Performance of ETFs - The innovative drug sector showed strong performance on November 12, with multiple related ETFs rising over 2.5% [1][4] - Defensive ETFs, including financial, consumer, large-cap value, and dividend ETFs, also exhibited significant gains [1][7] - The S&P Biotechnology ETF (159502) and NASDAQ Biotechnology ETF (513290) had notable increases, reflecting the positive trend in the overseas pharmaceutical market [4] Group 2: Fund Flows - The Huaan Gold ETF attracted over 1.4 billion yuan in net inflows over two trading days, driven by rising gold prices [3][9] - Consumer and AI-themed ETFs also saw substantial capital inflows, with several products like the Invesco Hang Seng Consumer ETF and Huatai-PineBridge CSI Major Consumer ETF leading in net inflows [9][10] - The financial sector ETFs, including the non-bank financial ETF, also reported significant net inflows, indicating a shift in investor interest [10] Group 3: Industry Insights - The innovative drug sector is expected to continue its growth trajectory, with a reported revenue increase of 1.98% and a net profit growth of 7.25% year-on-year for the third quarter [11] - The CXO sector showed even stronger performance, with revenue growth of 11.18% and net profit growth of 46.46% [11] - The overall outlook for the innovative drug industry remains positive, supported by domestic policy and a favorable global environment for drug development [11]